Intellia Therapeutics' Crispr-based treatment shows success in pivotal trial for hereditary angioedema
Intellia Therapeutics announced that its Crispr-based treatment for hereditary angioedema met its primary endpoint in a Phase 3 trial, reducing attacks by 87% compared to a placebo. The company plans to submit the treatment for FDA approval and aims for a 2027 launch if approved. The treatment is administered as a one-time infusion and showed favorable safety and tolerability.
Tickers: $NTLA
Topics: Crispr technology FDA approval gene editing hereditary angioedema medical innovation Phase 3 trial